Jefferies maintains that companies with mixed revenue streams, such as specialty pharma, biosimilars, and inhalers, may face ...
The company is expanding its cardiology portfolio with a new treatment for transthyretin amyloid cardiomyopathy in Europe.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results